| Title |
Danazol as first-line therapy for aplastic anemia
|
|---|---|
| Published in |
Annals of Hematology, January 2011
|
| DOI | 10.1007/s00277-011-1163-x |
| Pubmed ID | |
| Authors |
José Carlos Jaime-Pérez, Perla R. Colunga-Pedraza, Cynthia D. Gómez-Ramírez, César H. Gutiérrez-Aguirre, Olga G. Cantú-Rodríguez, Luz C. Tarín-Arzaga, David Gómez-Almaguer |
| Abstract |
Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) plus cyclosporine A (CsA) is the standard treatment for aplastic anemia (AA) patients not eligible for allogeneic hematopoietic stem cell transplantation (HSCT). In the absence of ATG + CsA, androgens continue to be a treatment option. We documented the clinical evolution of AA patients treated with danazol instead of ATG + CsA. AA patients lacking both, human leukocyte antigen-matched donor and access to IST, were treated with danazol and modern support therapy and compared with those receiving a HSCT. Overall survival (OS), response rates, and death risk odds were calculated. Fifty AA patients were studied. Thirteen received a HSCT and 37 danazol and support therapy. Median daily dose of danazol was 400 mg (300 to 600 mg), administered during a median of 12 months. Five-year OS was higher for patients receiving HSCT (92%) compared to the danazol group (41%) (P = 0.001). Overall response rate was 46% (17/37) in the danazol-treated group and the median time to initial response was 3 months (1-27). Tendency to achieve remission was similar among severity groups (P = 0.094). The only adverse side effect recorded on the danazol group was an episode of gastrointestinal bleeding. No patient treated with danazol suffered clonal evolution of his/her disease. Although ATG plus CsA is the therapy of choice for AA patients without a donor when neither HSCT nor IST is available, danazol remains an acceptable therapeutic option for AA patients. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Mexico | 1 | 2% |
| Unknown | 61 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 12 | 19% |
| Student > Bachelor | 11 | 17% |
| Researcher | 8 | 13% |
| Professor > Associate Professor | 5 | 8% |
| Student > Doctoral Student | 4 | 6% |
| Other | 12 | 19% |
| Unknown | 11 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 54% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Nursing and Health Professions | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 13 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 December 2023.
All research outputs
#2,352,512
of 25,016,456 outputs
Outputs from Annals of Hematology
#73
of 2,366 outputs
Outputs of similar age
#13,603
of 196,112 outputs
Outputs of similar age from Annals of Hematology
#2
of 14 outputs
Altmetric has tracked 25,016,456 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,366 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,112 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.